A pilot study investigating the effects of apixaban in patients with chronic disseminated intravascular coagulation (DIC)

A pilot study investigating the effects of apixaban in patients with chronic disseminated intravascular coagulation (DIC) - Apixaban in chronic DIC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027469

Enrollment

Registered

2017-05-23

Start date

2017-05-12

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Disseminated Intravascular Coagulation(Chronic DIC)

Interventions

Apixaban is administered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1 Patients with a history or present illness of severe allergy to a drug 2 Patients with severe renal disorder (< CLcr 30mL/min) 3 Patients whom the study drug might induce to bleed 4 Patients believed to die early even if they recovered from DIC, making it difficult to ensure a sufficient period of administration of the study drug and to obtain data on the efficacy and safety 5 Pregnant women, nursing mothers or possibly pregnant women 6 Patients whom the investigator considers to be unsuitable for participation in the study 7 Patients with severe hepatic disorder (< CLcr 30mL/min) 8 Patients with administration of other anticoagulants

Design outcomes

Primary

Measure	Time frame
Improvement of DIC score	—

Secondary

Measure	Time frame
Adverse event with apixaban (bleeding etc) Drug compliance	—

Countries

Japan

Contacts

Public ContactShohei Mizuno

Aichi Medical University Hospital Division of Hematology

shohei@aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026